The average one-year price target for Replimune Group (NasdaqGS:REPL) has been revised to $5.04 / share. This is a decrease of 59.94% from the prior estimate of $12.58 dated April 12, 2026. The price ...
Stocktwits on MSN
REPL ignites on doctor fury against FDA’s melanoma drug snub — health sec steps back
FDA refused to approve Replimune’s melanoma drug RP1 for the second time earlier this month citing insufficient data to ...
Replimune Group, Inc. (NASDAQ: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced multiple presentations at the 2026 American ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Replimune (REPL) stock plunged 19% after FDA issued second rejection of RP1 melanoma immunotherapy, citing inadequate trial design and controls.
Pomerantz LLP is investigating claims on behalf of investors of Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). Such investors are ...
At a Senate hearing, U.S. Health and Human Services Secretary Robert F. Kennedy Jr. said on Wednesday that he "had nothing to ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...
REPL EFFECT: Repl.it, an online programming and computing platform, has raised $4.5 million in a seed round led by two general partners, Marc Andreessen and Andrew Chen, from the venture capital firm ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results